Source: Annual Congress 2010 - Aspects of severe asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Micheletto, S. Tognella, F. Trevisan, M. Visconti, R. W. Dal Negro (Bussolengo, Italy). Effects of a 12-month course with omalizumab on nasal polyps and basement membrane in severe atopic asthma. Eur Respir J 2010; 36: Suppl. 54, 5473

Member's Comments

No comment yet.

Related content which might interest you: Effects of a 12-month course with omalizumab on basement membrane thickness in severe persistent atopic asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Anti-IgE and airway remodelling: Omalizumab affects reticular basement membrane thickness in severe persistent atopic asthma Source: Annual Congress 2011 - Immunology and cell biology of asthma and COPD Year: 2011 Effects of omalizumab on markers of eosinophilic inflammation in patients with severe allergic asthma Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Impact of mepolizumab in severe asthma with nasal polyps Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Clinical and histological impact of omalizumab in oral corticosteroid-dependent severe allergic asthma Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019 Airway autoimmunity and response to a 14-day course of oral corticosteroids in patients with severe eosinophilic asthma Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma Year: 2020 To assess the effects of combined nasal and inhaled corticosteroid in patients with asthma and persistent allergic rhinitis Source: Annual Congress 2009 - Clinical aspects of inflammatory airways diseases Year: 2009 Effects of add-on omalizumab therapy on airway wall thickening in severe persistent asthma Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011 The impact of targeted therapy in children with uncontrolled allergic persistent severe asthma and nasal polyps Source: International Congress 2017 – Paediatric asthma: therapies and comorbidities Year: 2017 Paracetamol and breakdown in epithelial barrier function in patients with asthma and atopic dermatitis Source: Annual Congress 2010 - Risk factors for allergic diseases in children Year: 2010 Efficacy of omalizumab in patients with concomitant allergic asthma and atopic dermatitis: a pilot study Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Efficacy of montelukast in patients with concomitan persistent allergic rhinitis and asthma Source: Eur Respir J 2006; 28: Suppl. 50, 663s Year: 2006 Differential treatment response to mepolizumab in severe eosinophilic asthma with nasal polyps Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 The ultrastructure of nasal mucosa in asthmatic children with and without allergic rhinitis Source: Eur Respir J 2005; 26: Suppl. 49, 398s Year: 2005 Effect of adding montelukast on asthma and rhinitis in asthma patients with concomitant allergic rhinitis Source: Eur Respir J 2006; 28: Suppl. 50, 121s Year: 2006 Dynamics of cytomorphologic picture of bronchial mucous membrane in asthma of therapy with budesonide Source: Eur Respir J 2005; 26: Suppl. 49, 341s Year: 2005 Impact of biologic therapy in severe asthma with nasal polyps Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Corticosteroid sensitivity, persistent airflow limitation and basement membrane thickening in children with asthma Source: Annual Congress 2008 - Treatment and outcome of childhood asthma: new perspectives Year: 2008 Allergic inflammation markers for earlier diagnosis of bronchial asthma in patients with allergic rhinitis Source: Annual Congress 2008 - Asthma: growing understanding of influential factors Year: 2008 Assesment of long-term omalizumab treatment in severe allergic asthma Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012